Cost-effectiveness of 10-year risk thresholds for initiation of statin therapy for primary prevention of cardiovascular disease

JAMA - Journal of the American Medical Association

Volumn 314, Issue 2, 2015, Pages 142-150

  Pandya, Ankur ^a   Sy, Stephen ^a   Cho, Sylvia ^a   Weinstein, Milton C ^a   Gaziano, Thomas A ^a,b  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ROSUVASTATIN; SIMVASTATIN;

ARTICLE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL (TOPIC); COHORT ANALYSIS; CORONARY ARTERY ATHEROSCLEROSIS; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DIABETES MELLITUS; DISEASE DURATION; DISEASE FREE INTERVAL; DRUG COST; DRUG EFFICACY; HUMAN; LIFE EXPECTANCY; META ANALYSIS (TOPIC); MYALGIA; MYOPATHY; PATIENT PREFERENCE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RHABDOMYOLYSIS; RISK ASSESSMENT; SENSITIVITY ANALYSIS; TREATMENT OUTCOME; UNITED STATES; ADULT; AGED; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; COST BENEFIT ANALYSIS; ECONOMICS; FEMALE; MALE; MIDDLE AGED; RISK;

ADULT; AGED; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; QUALITY-ADJUSTED LIFE YEARS; RISK;

EID: 84937423830     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2015.6822     Document Type: Article

References (57)

1. Stone NJ, Robinson JG, Lichtenstein AH, et al; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(25) (suppl 2):S1-S45.
2. Psaty BM,Weiss NS. 2013 ACC/AHA guideline on the treatment of blood cholesterol: a fresh interpretation of old evidence. JAMA. 2014;311(5): 461-462.
3. Goff DC Jr, Lloyd-Jones DM, Bennett G, et al; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J AmColl Cardiol. 2014;63(25 pt B):2935-2959.
4. Pencina MJ, Navar-Boggan AM, D'Agostino RB Sr, et al. Application of new cholesterol guidelines to a population-based sample. N Engl J Med. 2014; 370(15):1422-1431.
5. Guallar E, Laine C. Controversy over clinical guidelines: listen to the evidence, not the noise. Ann Intern Med. 2014;160(5):361-362.
6. Ridker PM, Cook NR. Statins: new American guidelines for prevention of cardiovascular disease. Lancet. 2013;382(9907):1762-1765.
7. Abramson JD, Redberg RF. Don't give more patients statins. http://www.nytimes.com/2013/11/14/opinion/dont-give-more-patients-statins.html?-r=0. Accessed June 9, 2015.
8. Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet. 2010;375(9716):735-742.
9. Krumholz HM. The new cholesterol and blood pressure guidelines: perspective on the path forward. JAMA. 2014;311(14):1403-1405.
10. Robinson JG. Accumulating evidence for statins in primary prevention. JAMA. 2013;310(22):2405-2406.
11. Dea?o RC, Pandya A, Jones EC, Borden WB. A look at statin cost-effectiveness in view of the 2013 ACC/AHA cholesterol management guidelines. Curr Atheroscler Rep. 2014;16(9):438.
12. Centers for Disease Control and Prevention (CDC). National Center for Health Statistics (NCHS). National Health and Nutrition Examination Survey. Hyattsville, MD: US Department of Health and Human Services, Centers for Disease Control and Prevention; 2011.
13. Baigent C, Keech A, Kearney PM, et al; Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospectivemeta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet. 2005;366(9493):1267-1278.
14. Zhang H, Plutzky J, Skentzos S, et al. Discontinuation of statins in routine care settings: a cohort study. Ann Intern Med. 2013;158(7):526-534.
15. Alsheikh-Ali AA, Ambrose MS, Kuvin JT, Karas RH. The safety of rosuvastatin as used in common clinical practice: a postmarketing analysis. Circulation. 2005;111(23):3051-3057.
16. Thomson Healthcare. Red Book. Montvale, NJ: Thomson PDR; 2014.
17. Jackevicius CA, Chou MM, Ross JS, Shah ND, Krumholz HM. Generic atorvastatin and health care costs. N Engl J Med. 2012;366(3):201-204.
18. Smith SL, Fischoff R, Klemp T; American Medical Association. Medicare RBRVS: The Physicians' Guide, 2011. Chicago, IL: American Medical Association; 2011.
19. O'Sullivan AK, Rubin J, Nyambose J, Kuznik A, Cohen DJ, Thompson D. Cost estimation of cardiovascular disease events in the United States. Pharmacoeconomics. 2011;29(8):693-704.
20. Lee KK, Cipriano LE, Owens DK, Go AS, Hlatky MA. Cost-effectiveness of using high-sensitivity C-reactive protein to identify intermediate- and low-cardiovascular-risk individuals for statin therapy. Circulation. 2010;122(15):1478-1487.
21. Pignone M, Earnshaw S, Tice JA, Pletcher MJ. Aspirin, statins, or both drugs for the primary prevention of coronary heart disease events in men: a cost-utility analysis. Ann Intern Med. 2006; 144(5):326-336.
22. Russell LB, Ibuka Y, Carr D. How much time do patients spend on outpatient visits?: the American time use survey. Patient. 2008;1(3):211-222.
23. US Bureau of Labor Statistics. Highlights of women's earnings in 2013. http://www.bls.gov/opub/reports/cps/highlights-of-womens-earnings-in-2013.pdf. Accessed June 9, 2015.
24. Gage BF, Cardinalli AB, Owens DK. The effect of stroke and stroke prophylaxis with aspirin or warfarin on quality of life. Arch Intern Med. 1996; 156(16):1829-1836.
25. Hutchins R, Viera AJ, Sheridan SL, Pignone MP. Quantifying the utility of taking pills for cardiovascular prevention. Circ Cardiovasc Qual Outcomes. 2015;8(2):155-163.
26. Sullivan PW, Ghushchyan V. Preference-based EQ-5D index scores for chronic conditions in the United States. Med Decis Making. 2006;26(4):410-420.
27. Pandya A,Weinstein MC, Salomon JA, Cutler D, Gaziano TA. Who needs laboratories and who needs statins?: comparative and cost-effectiveness analyses of nonlaboratory-based, laboratory-based, and staged primary cardiovascular disease screening guidelines. Circ Cardiovasc Qual Outcomes. 2014;7(1):25-32.
28. Gaziano TA, Opie LH,Weinstein MC. Cardiovascular disease prevention with a multidrug regimen in the developing world: a cost-effectiveness analysis. Lancet. 2006;368 (9536):679-686.
29. Gaziano TA, Steyn K, Cohen DJ,Weinstein MC, Opie LH. Cost-effectiveness analysis of hypertension guidelines in South Africa: absolute risk vs blood pressure level. Circulation. 2005;112 (23):3569-3576.
30. Vanni T, Karnon J, Madan J, et al. Calibrating models in economic evaluation: a 7-step approach. Pharmacoeconomics. 2011;29(1):35-49.
31. Anderson KM, Odell PM, Wilson PW, Kannel WB. Cardiovascular disease risk profiles. Am Heart J. 1991;121(1 pt 2):293-298.
32. Wolf PA, D'Agostino RB, Belanger AJ, Kannel WB. Probability of stroke: a risk profile from the Framingham Study. Stroke. 1991;22(3):312-318.
33. Pandya A, Gaziano TA,Weinstein MC, Cutler D. More Americans living longer with cardiovascular disease will increase costs while lowering quality of life. Health Aff (Millwood). 2013;32(10):1706-1714.
34. Heron M. Deaths: Leading Causes for 2006. National Vital Statistics Reports. Vol 58. Hyattsville, MD: National Center for Health Statistics; 2010.
35. Smolina K,Wright FL, Rayner M, GoldacreMJ. Long-term survival and recurrence after acute myocardial infarction in England, 2004 to 2010. Circ Cardiovasc Qual Outcomes. 2012;5(4):532-540.
36. Ford ES, Roger VL, Dunlay SM, Go AS, Rosamond WD. Challenges of ascertaining national trends in the incidence of coronary heart disease in the United States. J AmHeart Assoc. 2014;3(6): e001097.
37. White AD, Folsom AR, Chambless LE, et al. Community surveillance of coronary heart disease in the Atherosclerosis Risk in Communities (ARIC) Study:methods and initial 2 years' experience. J Clin Epidemiol. 1996;49(2):223-233.
38. FeinleibM, Kannel WB, Garrison RJ, McNamara PM, Castelli WP. The Framingham Offspring Study: Design and preliminary data. Prev Med. 1975;4(4): 518-525.
39. National Heart Lung and Blood Institute (NHLBI). Incidence and prevalence: 2006 chart book on cardiovascular and lung diseases. http://www.nhlbi.nih.gov/sites/www.nhlbi.nih.gov/files/06-ip-chtbk.pdf. Accessed June 9, 2015.
40. Centers for Disease Control and Prevention (CDC). National Center for Health Statistics (NCHS). National Health and Nutrition Examination Survey Data. Hyattsville, MD: US Department of Health and Human Services, Centers for Disease Control and Prevention; 2014.
41. van Kempen BJ, Ferket BS, Hofman A, Spronk S, Steyerberg E, Hunink MG. Do different methods of modeling statin treatment effectiveness influence the optimal decision? Med Decis Making. 2012;32 (3):507-516.
42. Agency for Healthcare Research and Quality (AHRQ). Medical expenditure panel survey. http://meps.ahrq.gov/data-stats/download-data-files-detail.jsp?cboPufNumber=HC-036. Accessed January 23, 2015.
43. Greving JP, Visseren FL, deWit GA, Algra A. Statin treatment for primary prevention of vascular disease: whom to treat? cost-effectiveness analysis. BMJ. 2011;342:d1672.
44. Avorn J, Monette J, Lacour A, et al. Persistence of use of lipid-lowering medications: a cross-national study. JAMA. 1998;279(18):1458-1462.
45. Optum. DRG Expert: A Comprehensive Guidebook to the DRG Classification System. Salt Lake City, UT: OPTUMInsight; 2014.
46. Hunink MM,Weinstein MC, Wittenberg E, et al. Decision Making in Health and Medicine: Integrating Evidence and Values. 2nd ed. Cambridge, UK: Cambridge University Press; 2014.
47. Weinstein MC, Siegel JE, GoldMR, Kamlet MS, Russell LB. Recommendations of the Panel on Cost-effectiveness in Health and Medicine. JAMA. 1996;276(15):1253-1258.
48. Neumann PJ, Cohen JT,Weinstein MC. Updating cost-effectiveness-the curious resilience of the $50 000-per-QALY threshold. N Engl JMed. 2014;371(9):796-797.
49. Rosenbaum L. Beyond belief-how people feel about taking medications for heart disease. N Engl J Med. 2015;372(2):183-187.
50. Prosser LA, Stinnett AA, Goldman PA, et al. Cost-effectiveness of cholesterol-lowering therapies according to selected patient characteristics. Ann Intern Med. 2000;132(10):769-779.
51. Pletcher MJ, Lazar L, Bibbins-Domingo K, et al. Comparing impact and cost-effectiveness of primary prevention strategies for lipid-lowering. Ann Intern Med. 2009;150(4):243-254.
52. Lazar LD, Pletcher MJ, Coxson PG, Bibbins-Domingo K, Goldman L. Cost-effectiveness of statin therapy for primary prevention in a low-cost statin era. Circulation. 2011;124(2):146-153.
53. Ridker PM. The JUPITER trial: results, controversies, and implications for prevention. Circ Cardiovasc Qual Outcomes. 2009;2(3):279-285.
54. Muntner P, Colantonio LD, Cushman M, et al. Validation of the atherosclerotic cardiovascular disease Pooled Cohort risk equations. JAMA. 2014; 311(14):1406-1415.
55. Eddy DM, HollingworthW, Caro JJ, Tsevat J, McDonald KM,Wong JB. Model transparency and validation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-7. Med Decis Making. 2012;32(5):733-743.
56. Unal B, Capewell S, Critchley JA. Coronary heart disease policy models: a systematic review. BMC Public Health. 2006;6:213.
57. Coles AH, Fisher KA, Darling C, et al. Recent trends in postdischarge mortality among patients with an initial acutemyocardial infarction. Am J Cardiol. 2012;110(8):1073-1077.